First report of pediatric hematopoietic stem cell transplantation activities in the eastern mediterranean region from 1984 to 2011: on behalf of the pediatric cancer working committee of the eastern mediterranean blood and marrow transplantation group.
To describe the hematopoietic stem cell transplantation (HSCT) activities for children in the Eastern Mediterranean (EM) region, data on transplants performed for children less than 18 years of age between 1984 and 2011 in eight EM countries (Egypt, Iran, Jordan, Lebanon, Oman, Pakistan, Saudi Arabia and Tunisia) were collected. A total of 5187 transplants were performed, of which 4513 (87%) were allogeneic and 674 (13%) were autologous. Overall, the indications for transplantation were malignant diseases in 1736 (38.5%) and non-malignant in 2777 (61.5%) patients. A myeloablative conditioning regimen was used in 88% of the allografts. Bone marrow (BM) was the most frequent source of stem cells (56.2%), although an increasing use of PBSC was observed in the last decade. The stem cell source of autologous HSCT has shifted over time from BM to PBSC, and 80.9% of autologous HSCTs were from PBSCs. The donors for allogeneic transplants were matched-related in 94.5% of the cases, and unrelated transplants, mainly cord blood (99%) in 239 (5.5%) cases. This is the first report to describe the pediatric HSCT activities in EM countries. Non-malignant disorders are the main indication for allogeneic transplantation. Frequency of alternate donor transplantation is low.
Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
A A
AA
Hussein
Hematology, Oncology and SCT Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
A A
AA
Hamidieh
National Cancer Institute, Cairo University, Cairo, Egypt.
A
A
Elhaddad
Shiraz University of Medical Science, Shiraz, Islamic Republic of Iran.
M
M
Ramzi
Center National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.
T B
TB
Othman
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
F
F
Hussain
Sultan Qaboos University Hospital, Muscat, Oman.
D
D
Dennison
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.
P
P
Ahmed
American University Beirut Medical Center, Beirut, Lebanon.
M
M
Abboud
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
A
A
Al-Ahmari
Queen Rania Al-Abdullah Children Hospital-King Hussein Medical Center, Amman, Jordan.
A
A
Wahadneh
National Cancer Institute, Cairo University, Cairo, Egypt.
J
J
Fathy
Oran University-1st November Hospital, Oran, Algeria.
M-A
MA
Bekadja
Sultan Qaboos University Hospital, Muscat, Oman.
S
S
Al-Kindi
Service d'Hematologie et Oncologie Pediatrique, Casablanca, Morocco.
S
S
Benchekroun
Makassed General Hospital, Beirut, Lebanon.
A
A
Ibrahim
Hematology, Oncology and SCT Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
M
M
Behfar
National Cancer Institute, Cairo University, Cairo, Egypt.
M
M
Samra
Center National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.
S
S
Ladeb
Aga Khan University Hospital, Karachi, Pakistan.
S
S
Adil
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
H
H
El-Solh
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
M
M
Ayas
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
M
M
Aljurf
Hematology, Oncology and SCT Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
A
A
Ghavamzadeh
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
A
A
Al-Seraihy
D000293:Adolescent; D064591:Allografts; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D019083:Mediterranean Region / Q000453:epidemiology; D009369:Neoplasms / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies; D019172:Transplantation Conditioning